DIFFUSE LARGE B-CELL LYMPHOMA

This study tested a new drug called BGB-10188, alone or combined with other cancer drugs, in 97 people with certain blood cancers (like lymphoma and leukemia) or advanced solid tumors. The main goals were to find safe doses and check for side effects. The trial was completed, but…

This phase 3 trial tested adding the drug tucidinostat to standard chemotherapy (R-CHOP) in 423 adults with a fast-growing type of lymphoma called double-expressor DLBCL. The goal was to see if the combination could delay the cancer from coming back or getting worse. Participants…

This early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study was completed, but results are no…

This study looked at 174 adults with blood cancers who received a stem cell transplant from an unrelated donor. Researchers compared different combinations of immune-suppressing drugs to find the best way to prevent graft-versus-host disease (GVHD), a serious complication where d…

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant can help keep lymphoma from coming back. It included 82 people with Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma that had returned or not responded to prior t…

This study tested a new radiation schedule (once a week for 5 weeks) in 10 people with B-cell lymphoma that had come back or not responded to treatment. The goal was to see if this approach is practical and has fewer side effects before patients receive CAR T-cell therapy. The st…

This study tested whether adding lenalidomide to standard chemotherapy (R-CHOP) could improve outcomes for people with a fast-growing type of lymphoma called diffuse large B-cell lymphoma. The trial included 60 patients with medium-to-high risk disease who had not yet received tr…

This study tested adding lenalidomide to standard chemotherapy (RICE) for people with diffuse large B-cell lymphoma that returned after initial treatment. The goal was to improve response rates so more patients could proceed to a stem cell transplant and potentially live longer. …

This early-phase study tested a chemotherapy regimen called dose-adjusted EPOCH-R in 4 children with certain B-cell cancers (DLBCL, PMBCL, or PTLD). The goal was to see if giving the drugs continuously over 4 days and adjusting doses based on blood cell counts is safe and effecti…

This early-phase study tested a new combination of drugs (romidepsin plus standard chemotherapy) in 21 patients with two types of lymphoma. The main goal was to find the safest dose and understand side effects. Researchers hope this approach could lead to better outcomes, but mor…

This early-stage study tested a new treatment called C-CAR066 in 7 adults with diffuse large B-cell lymphoma whose cancer returned or didn't respond after a prior CAR-T therapy. The treatment uses a patient's own immune cells, modified to target the CD20 protein on cancer cells. …

This study tested whether adding the drug polatuzumab vedotin to a standard chemotherapy regimen (R-GEMOX) helps people with diffuse large B-cell lymphoma that has come back or not responded to previous treatment. The trial involved 270 adults and compared the combination against…

This early-phase study tested an experimental therapy called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The main goal was to find the safest dose and see if the treatment could shrink tumors. B…

This early-phase study tested a new treatment called BZ019 in 12 adults with certain types of B-cell lymphoma that had stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals were to check safety and…

This large Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the current standard (R-CHOP) for people with untreated diffuse large B-cell lymphoma, a common and aggressive blood cancer. About 1000 particip…

This study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot take a common chemotherapy drug called anthracycline. The trial compared a newer drug (inotuzumab ozogamicin) plus standard therapy aga…

This study looked at how safe and effective a combination of two drugs (tafasitamab and lenalidomide) is for people with a type of blood cancer called diffuse large B-cell lymphoma that has returned or stopped responding to treatment. The study focused on including patients from …

This study tested the drug chidamide as a maintenance therapy for 30 people with hepatitis B virus (HBV)-positive diffuse large B-cell lymphoma who had already achieved complete remission after chemotherapy. The goal was to see if chidamide could help keep the cancer from returni…

This study looked at how levels of tumor DNA in the blood change in the hours after the first dose of chemotherapy for diffuse large B-cell lymphoma. Researchers wanted to find the best time to take blood samples for monitoring. The study included 24 adults who were starting trea…

This study looked at how genetic differences affect the body's ability to clear high-dose methotrexate in patients with diffuse large B-cell lymphoma. Researchers analyzed DNA from 20 participants to find specific gene variations linked to slower drug clearance. The goal was to b…

This study looked at 60 people with a type of blood cancer called diffuse large B-cell lymphoma. Researchers used advanced techniques to examine individual cells from tumors and blood samples. The goal was to find markers that could help track how the disease changes over time an…

This study followed 60 adults with diffuse large B-cell lymphoma who were scheduled to receive a standard CAR T-cell therapy called axi-cel. Researchers measured changes in memory, attention, thinking skills, and quality of life using questionnaires and tests. The goal was to und…